Non-small cell lung cancer
Conditions
Interventions
Case group:None
Control group:None
Sponsors
Quzhou People Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Healthy people Inclusion Criteria: 1.15 6.5% or fasting blood glucose >126 mg/dL or taking diabetes medication or insulin therapy); j. Recent cardiovascular disease events (myocardial infarction, coronary intervention, coronary artery bypass grafting); k. Infectious diseases such as HIV, hepatitis, tuberculosis, etc.; l. Hand or lower limb disability that interferes with normal function and life. 4. Able to communicate well with the investigator and be able to cooperate with various tasks during the research period. 5. Written informed consent can be signed voluntarily. Patients with non-small cell lung cancer Inclusion Criteria: 1. Age 40-60 years old, 15 = BMI= 28, male or female. 2. Local residents of Quzhou or have lived in Quzhou for the past 10 years and have no major bad habits. 3. No other malignant tumors or history of tumors except non-small cell lung cancer. 4. Tumor does not have orthotopic and distant metastases (mainly stage IA-II). 5. Have not used any chemotherapy drugs within 2 years prior to enrollment. 6. Able to communicate well with the investigator and be able to cooperate with various tasks during the research period. 7. Written informed consent can be signed voluntarily.
Exclusion criteria
Exclusion criteria: Healthy people Exclusion Criteria: 1. Women who are pregnant, lactating or suffering from premature ovarian failure, hysterectomy/endometrial dissection. 2. Currently taking the following medications: a. Chemotherapy drugs (e.g. tamoxifen, doxorubicin, etc.); b. Antiplatelet agents (e.g., clopidogrel/plavix, dipyridine/anglenol, ticlopidine/ticlopidine, except aspirin); c. Cholinesterase inhibitors (e.g., donepezil/alicept). 3. Treatment with any investigational drug or device within 30 days prior to enrollment, or participation in any other clinical trial within 3 months prior to enrollment, or injection of vaccine within half a month prior to enrollment. Patients with non-small cell lung cancer Exclusion Criteria: 1. Women with premature ovarian failure, hysterectomy/endometrial dissection. 2. Currently taking the following medications: a. Chemotherapy drugs (e.g. tamoxifen, doxorubicin, etc.); b. Antiplatelet agents (e.g., clopidogrel/plavix, dipyridine/anglenol, ticlopidine/ticlopidine, except aspirin); c. Cholinesterase inhibitors (e.g., donepezil/alicept). Treatment with any investigational drug or device within 30 days prior to enrollment, or participation in any other clinical trial within 3 months prior to enrollment, or vaccine injection within half a month prior to enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum NAD+ level; | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone density;Grip strength test;FVC;Flexibility of fingers; | — |
Countries
China
Contacts
Public ContactZhang Feng
Quzhou People Hospital
Outcome results
None listed